Overview
- Hims & Hers said it will offer a compounded oral semaglutide pill for an introductory $49, undercutting Novo Nordisk’s branded Wegovy pill listed at about $149.
- Following the initial month, a five-month subscription prices refills at $99 per month, compared with $199 cited for Novo’s plan, according to Hims and Reuters.
- Investors reacted immediately as Novo Nordisk shares fell about 7%, Eli Lilly dropped roughly 6.1%, and Hims & Hers rose around 10%, according to CNBC.
- The FDA warned Hims in September that claims equating compounded semaglutide to Ozempic or Wegovy are misleading because compounded drugs are not FDA-approved.
- Semaglutide patents run until 2032, and Hims argues its personalized compounding is lawful, while Novo urges states to curb large-scale copies and Lilly’s rival oral pill is anticipated pending FDA approval.